April 17, 2024
Bio
Genexine to begin clinical trials of HPV-induced cervical cancer drug
[THE INVESTOR] South Korean biopharmaceutical company Genexine said on Dec. 1 that it will kick off the clinical trials to assess its cervical cancer and infectious diseases treatment following an approval by the country’s health agency.
The Ministry of Food and Drug Safety approved on Nov. 30 the phase 1 clinical study of Genexine’s GX-I7, the treatment of persistent human papilloma virus infections and solid tumors, according to the company.
Human papillomavirus causes almost all cases of cervical cancer.
Genexine has been conducting the phase 1 trials of the drug as a treatment for lymphocytopenia since June.
By Park Han-na (hnpark@heraldcorp.com)
The Ministry of Food and Drug Safety approved on Nov. 30 the phase 1 clinical study of Genexine’s GX-I7, the treatment of persistent human papilloma virus infections and solid tumors, according to the company.
Human papillomavirus causes almost all cases of cervical cancer.
Genexine has been conducting the phase 1 trials of the drug as a treatment for lymphocytopenia since June.
By Park Han-na (hnpark@heraldcorp.com)
